AstraZeneca is buying Fusion Pharmaceuticals, a Canadian company specializing in radioconjugation cancer treatments, for $2.4 billion.
Petru Nicolaescu
Health
Unsplash.com
Always see our news on Google
The acquisition of Fusion Pharmaceuticals by AstraZeneca brings innovative new treatments to the company's portfolio. Radioconjugates developed by Fusion are an alternative to chemotherapy and radiotherapy, minimizing damage to healthy cells. The most advanced treatment, FPI-2265, is for patients with metastatic prostate cancer.
Latest News
14:26
The Rabla Program: funds amounting to over 35 million lei were exhausted in less than an hour
14:17
Sorana Cîrstea defeated Maria Timofeeva to advance to the last 16 of the WTA 250 tournament in Hong Kong
14:09
Alexandru Rogobete extends oversight to the “Socola” Psychiatric Hospital in Iași / Inspectors will check every ward
14:08
Von der Leyen calls for a single authorization for the use of autonomous vehicles in the EU
14:00
The Health Minister’s reaction after criticism regarding the luxury displayed by some Social Democrats at the christening party in Timișoara: In general, it is best not to generalize
See more news
NEWS ON THE SAME TOPICS
IT&C knowledge
Novo collaborates with Anthropic to use artificial intelligence in the research and development of new medicines
International
An experimental cancer vaccine, developed by Moderna and Merck, has shown promising results in patients with melanoma.
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
